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Oprean: Counter Attack

Counter Attack
Developing new weapons in the battle against antibiotic resistance
by Amy Oprean

I

n the course of human medicine, few discoveries

known is its job of containing the genetic “recipe”

have been as far-reaching and successful as the

for synthesizing proteins. RNA’s role has been

development of antibiotics in the 20th century.

highly conserved throughout evolution – organisms

Introduced to mainstream medicine in the 1940s,

from bacteria all the way to humans depend on its

these drugs have been utilized to vanquish a vast

functions.
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array of bacterial infections, relieving the suffering
and saving the lives of millions of people. But
antibiotics aren’t the surefire defense they used

antibiotics. The RNA of bacteria is one of the two

to be. A drop in research over the past several

most common targets for antibiotics – the other

decades in developing new antibiotics, coupled with

being enzymes that synthesize bacteria’s cell walls –

bacteria’s evolutionary drive to develop resistance,

for several reasons, Dr. Chow explained. First, RNA

has caused the number of effective antibiotics to

is more chemically and structurally diverse than

diminish, and with increasing speed.

other possible target areas, such as DNA, meaning

Christine Chow, Ph.D., professor of Chemistry in
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Dr. Christine Chow, professor of chemistry
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Being such an important aspect of all life
also makes RNA an incredibly useful target for

RNA has an abundance of unique structures for an

Wayne State’s College of Liberal Arts and Sciences,

antibiotic to “latch on to.” It’s also more accessible

is leading a research team in developing a novel

than DNA, and doesn’t have the defense enzymes

strategy to get an edge over bacteria’s relentlessly

that protect DNA. Lastly, RNA comprises the

evolving defense mechanisms. “Resistance is a huge

physical structure of the ribosome, RNA-protein

problem,” Dr. Chow said. “There are now strains

complexes that are found in all living organisms.

of bacteria that are completely resistant to every

Ribosomes perform the essential function of

known drug. We want to create something new that

synthesizing all the proteins in an organism. Like

isn’t as easy for bacteria to resist.”

RNA itself, these protein-making machines can be

The key to Dr. Chow’s research lies in ribonucleic

found from bacteria all the way up to humans, and

acid, or RNA, a nucleic acid that consists of a long

are important to maintaining all life. Because of this

chain of nucleotide units, chemically similar to

importance, ribosomes are already one of the most

DNA, but consisting of one chain of nucleotides

common targets of antibiotics – one of simplest

instead of DNA’s double helix. RNA has a diverse

ways to eliminate unwanted bacteria is to shut

set of functions, but one of the basic and most well-

down its ribosomes.

1

Chow’s strategy for battling antibiotic resistance
takes the tried and true method of targeting a
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Finding the weapon
With the targets of the “protein machine”

she develops. She is collaborating with Phil
Cunningham, Ph.D., associate professor of biology

bacteria cell’s ribosomes and aims to improve it, by

chosen, Chow’s task at hand is finding a chemical

in WSU’s College of Liberal Arts and Sciences, to

targeting sites that are particularly vulnerable and

“monkey wrench” that will bind to a ribosome

utilize the genetic system Cunningham developed

attacking with a compound the bacteria has never

and shut down its protein production. The process

that predicts “functional mutants” – the potential

seen before. “If your antibiotics are derived from

will involve several steps, beginning with finding

mutations bacterial RNAs are likely to take on.

natural compounds, there has already been time

a compound that has an affinity for one of the

“We’re trying to do a screening to find compounds

for the bacteria to evolve resistance mechanisms,

modified sites, and will bind to it. “If there is a

that bind to functional mutants, so once the

and that’s why we have this big problem with

strong interaction, that means the compound has

bacteria develops a mutation to an antibiotic, we’ll

antibiotic resistance,” she said. “So we want to find

potential to be a drug,” Dr. Chow said. “The next

already have a drug ready,” she said.

compounds that don’t look like anything from

step is to look and see if it affects the ribosome

nature. That way, resistance mechanisms
will hopefully take longer to develop.”

Selecting a target
Just like DNA, RNA’s “genetic code” is
subject to modifications – changes in either

function. In other words, does it stop protein
synthesis? If that does happen, that’s great, but

to defend against. “Our hope is to find a lead

there is still another question, which is, can this

compound, something that could potentially lead

compound get into cells? If the drug never gets

to an antibiotic,” she said. “If not, we’ll at least

into the cells, then it can’t kill them.”

learn a lot about the rules for how compounds bind

To find additional information on the nature of

and that would help other people to design

its chemical make-up or structure that enable it to

bacterial RNA, Chow is also performing these trials

carry out vital functions. With her lab, Chow has

on the corresponding modified RNA sites in human

selected regions of RNA with six different natural

ribosomes, looking for any functional or structural

modifications as potential antibiotic targets. Chosen

differences that will further her understanding of

for their importance to ribosome function, Chow’s

bacterial RNA at these modified sites. “We want to

lab is synthesizing these modified portions of RNA,

know if the function of these modifications is the

using miniaturized versions of the full scale RNAs so

same in both organisms” she said. “We believe that

that individual nucleotides can be monitored more

even though the modifications occur in both, they

closely. All six modified portions of RNA are located

might have slightly different roles or effects on the

at different places on the physical structure of the

RNA. And what we really want to do is determine

ribosome, and are believed to control such vital

the differences so that we can take advantage of

processes as the maintenance of protein assembly

them for drug targeting.”

and control of turning protein synthesis on and off.

new drugs.”

About Dr. Christine Chow:

Dr. Chow received an A.B.

in environmental studies and chemistry from Bowdoin College
and an M.A. in organic chemistry from Columbia University. She

✼

studied inorganic chemistry with a focus on the interactions
of transition metal complexes with RNA at the California
Institute of Technology, where she earned a Ph.D. She then
became a National Institutes of Health postdoctoral fellow
at the Massachusetts Institute of Technology, studying the
interactions of proteins with DNA modified by the anticancer
drug Cisplatin. She joined Wayne State University in 1994.

Even with the advantage of brand new chemical

“We wanted to target areas that are very essential

compounds, however, Chow knows that bacteria

for the survival of cells,” she said.

may still develop resistance to the antibiotics
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In the meantime, Chow is hard at work looking
for a drug that will be a new challenge for bacteria
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